Risk Factors for mortality among patients with pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes?

dc.contributor.authorMontero, Maria Milagro
dc.contributor.authorLópez Montesinos, Inmaculada
dc.contributor.authorKnobel Freud, Hernando
dc.contributor.authorMolas, Ema
dc.contributor.authorSorli Redó, M. Luisa
dc.contributor.authorSiverio, Ana
dc.contributor.authorPrim, Núria
dc.contributor.authorSegura, Concepción
dc.contributor.authorDuran Jordà, Xavier, 1974-
dc.contributor.authorGrau Cerrato, Santiago
dc.contributor.authorHorcajada Gallego, Juan Pablo
dc.date.accessioned2021-04-27T06:20:21Z
dc.date.available2021-04-27T06:20:21Z
dc.date.issued2020
dc.description.abstractThis study aimed to assess the impact of extensively drug-resistant (XDR) phenotype on mortality in Pseudomonas aeruginosa bacteremia. A retrospective cohort study was performed in a tertiary hospital from January 2000 to December 2018. All consecutive prospectively recorded P. aeruginosa bacteremia in adult patients were assessed. In this study, 382 patients were included, of which 122 (31.9%) due to XDR P. aeruginosa. Independent factors associated with 14-day mortality were as follows: high-risk source of bacteremia (hazard ratio (HR) 3.07, 95% confidence interval (CI), 1.73-5.46), septic shock (HR 1.75, 95% CI, 1.12-2.75), and higher Pitt scores (one-point increments; HR 1.25, 95% CI, 1.12-1.38). Otherwise, the appropriateness of definitive antibiotic therapy was a protective factor (HR 0.39, 95% CI, 0.24-0.62). The same variables were also associated with 30-day mortality. XDR phenotype was not associated with 14- or 30-day mortality. In a subanalysis considering only high-risk source cases, combined antimicrobial therapy was independently associated with 14-day favorable outcome (HR 0.56, 95% CI, 0.33-0.93). In conclusion, XDR phenotype was not associated with poor prognosis in patients with P. aeruginosa bacteremia in our cohort. However, source of infection, clinical severity, and inappropriate definitive antibiotic therapy were risk factors for mortality. Combined antimicrobial therapy should be considered for high-risk sources.
dc.format.mimetypeapplication/pdf
dc.identifier.citationMontero MM, López Montesinos I, Knobel H, Molas E, Sorlí L, Siverio-Parés A, et al. Risk Factors for mortality among patients with pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes?. J Clin Med. 2020 Feb 14; 9(2): 514. DOI: 10.3390/jcm9020514
dc.identifier.doihttp://dx.doi.org/10.3390/jcm9020514
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/10230/47212
dc.language.isoeng
dc.publisherMDPI
dc.rightsCopyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.keywordBacteremia
dc.subject.keywordCombined antimicrobial therapy;
dc.subject.keywordExtensively drug-resistant Pseudomonas aeruginosa
dc.subject.keywordHigh-risk clones
dc.subject.keywordMultidrug resistance
dc.subject.keywordOutcome
dc.titleRisk Factors for mortality among patients with pseudomonas aeruginosa bloodstream infections: what is the influence of XDR phenotype on outcomes?
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
montero-jcm-risc.pdf
Size:
627.02 KB
Format:
Adobe Portable Document Format

License

Rights